item management s discussion and analysis of financial condition and results of operations overview the company s founding vision and strategic focus is the creation of a virtual hospital room for the alternate site health care market 
from its inception in through mid  the company was in its development stage and engaged primarily in research and development  product engineering and activities related to obtaining clearance from the fda for its first product  the stationary pump 
the company has six years of operating history and  although profitable since the third quarter of  experienced significant operating losses from its inception through mid upon receiving fda clearance for the stationary pump in mid  the company focused its efforts on creating a domestic and international sales and marketing network  as well as a manufacturing capability  to assist in the distribution of its first product to the alternate site health care market 
concurrent with these sales and marketing activities  the company continued to fund the research  development and regulatory clearance activities of other device and software products 
the company commercially launched the ambulatory pump and related disposable supplies in late and both mediview and the pumpmaster r in late since then  the company has continued its sales and marketing activities domestically and internationally for the distribution of its products and continued to fund the research and development of additional products 
on february   the company acquired substantially all the assets of rocap which produces and markets pre packaged injectable prescription pharmaceuticals and pre filled flush syringes 
in addition  the company derives revenues from the servicing of products and sale of accessories and extended warranties 
the company sells its products both directly to alternate site and acute care providers  as well as to third party distributors 
the company s distributors and customers may purchase several months of inventory at any one time which may cause fluctuations in quarterly revenues 
the company also markets and sells its products internationally and  as a result  its revenues may be affected by fluctuations in exchange rates 
failure to obtain regulatory approval for the distribution of new products domestically or in international markets  or adverse regulatory changes  may also affect the revenues of the company 
the company has entered into strategic partnerships  including unitron and gds  which provide components of the virtual hospital room 
management intends to pursue additional acquisition and partnering opportunities in order to further accelerate the development of the virtual hospital room 
results of operations years ended december  and net sales 
net sales increased million to million for the year ended december  as compared to million for the year ended december   an increase of 
the increase is attributable to several factors  incremental unit sales volume of the stationary pump and ambulatory pump and their respective disposables into the alternate site health care market including national homecare companies  an increase in the average per unit selling price due to a higher ratio of direct sales versus dealer sales  the addition of the rocap product line of pre filled flush syringes in february   the addition of the mediview and pumpmaster products  and the addition of certain licensed products from gds technology  inc cost of sales 
cost of sales increased million to million for the year ended december   as compared to million for the year ended december   an increase of 
the increase is primarily attributable to direct product costs associated with incremental unit sales volume of the and infusion pumps and related disposables  the addition of the rocap product line and an increase in costs relating to the expansion of production capacity 
gross margin 
gross margin increased million to million for the year ended december  as compared to million for the year ended december   an increase of 
the increase is due primarily to the incremental unit sales volume and per unit contribution thereon  including the economies of scale realized by allocating fixed manufacturing costs over a greater number of units 
also contributing to the increase were higher average pricing levels  a more favorable product mix of the ambulatory pump units to stationary pump units  and the addition of the rocap product line 
gross margin as a percent of sales increased to for the year ended december  as compared to for the year ended december  selling  general and administrative expenses 
selling  general and administrative expenses increased million to million for the year ended december  as compared to million for the year ended december   an increase of 
the increase is due primarily to the expansion of the company s direct sales force and clinical support staff and the associated travel thereby  as well as  greater aggregate commissions paid in conjunction with higher net sales 
contributing also to the increase for the year ended december  was the assumption of expenses relating to the rocap product line  the addition of administrative and management personnel  as well as the expansion of the niles  illinois facility 
expenses relating to sims deltec  inc litigation were approximately  for the year ended december  selling  general and administrative expenses as a percent of sales decreased to for the year ended december  as compared to for the year ended december  operating income 
operating income increased to million for the year ended december  as compared to  for the year ended december   an increase of 
operating income as a percent of sales increased to for the year ended december  as compared to for the year ended december  the increase in operating income is due primarily to incremental gross margin generated by increased unit sales volume of new and existing products  as described above 
interest income 
interest income increased to million for the year ended december  as compared to  for the year ended december   an increase of 
the increase is attributable to a higher average balance of cash available for investment as compared to that of the year ended december  the company completed a secondary public offering in april  which resulted in net proceeds to the company of approximately million 
in june   the company completed an initial public offering which resulted in net proceeds to the company of approximately million 
interest expense 
interest expense decreased to  for the year ended december  as compared to  for the year ended december   a decrease of 
the decrease for the year ended december  is primarily attributable to the conversion and elimination of all convertible debt outstanding at the company s initial public offering in june  interest expense for the year ended december  applies to capital lease obligations and borrowings collateralized by a certain customer receivable 
stock appreciation rights expense 
no stock appreciation rights expense is recorded for the year ended december  as compared to million for the year ended december  the stock appreciation rights expense for the year ended december  was non recurring 
provision for income taxes 
due to net operating loss carryforwards sufficient enough to offset pretax income  the company did not incur any federal or state income tax liability for the year ended december  due to net losses for the year ended december   the company did not incur any federal or state income tax liability for the period 
utilization of remaining net operating loss carryforwards depends on future earnings and will be subject to annual limitations as a result of changes that have occurred in the company s ownership 
net income 
net income was million for the year ended december  as compared to a net loss of  for the year ended december  net income for the year ended december  was achieved primarily as a result of incremental gross margin generated by increased unit sales volume of new and existing products  as discussed above 
also contributing to net income for the year ended december  was the increase in interest income due to the investment of excess cash 
additionally  the year ended december  included the non recurring charge for stock appreciation rights of million 
years ended december  and net sales 
net sales increased to million for the year ended december  from million for the year ended december   an increase of million or 
the increase is primarily attributable to an increase in sales volume of the stationary pump  the ambulatory pump and their respective disposables  to the alternate site health care market 
also contributing to the increase was the introduction of the mediview and pumpmaster products 
cost of sales 
cost of sales increased to million for the year ended december  from million for the year ended december   an increase of million  or 
approximately million of the increase represents the direct manufacturing cost attributable to the increase in sales volume and the balance of the increase is attributable to the investment in fixed manufacturing costs and overhead necessary to increase production capacity 
gross margin 
gross margin increased to million for the year ended december  from million for the year ended december   an increase of million  or 
the increase is due primarily to the increase in sales volume and the resulting economies of scale associated with the increase 
gross margin as a percentage of sales increased to for the year ended december   from for the year ended december  the increase is due to the absorption of fixed manufacturing costs and overhead over a greater unit volume  higher average pricing levels for the stationary pump  and the higher margins inherent to the ambulatory pump introduced in the fourth quarter of selling  general and administrative expenses 
selling  general and administrative expenses increased to million for the year ended december  from million for the year ended december   an increase of million  or 
expansion of the company s sales and clinical support staff increased selling  general and administrative expenses by approximately million while reductions and elimination of financial  marketing and product development consulting fees represent the offsetting amount 
selling  general and administrative expenses as a percent of sales decreased to for the year ended december  from for the year ended december  the decrease is due to the allocation of overhead expenses over a greater volume of sales 
operating income loss 
the company reported operating income of  for the year ended december  as compared to an operating loss of million for the year ended december  the primary contributors to operating profitability  as discussed above  are the incremental sales volume of the stationary pump and the ambulatory pump and related products 
interest expense 
interest expense increased to  for the year ended december  from  for the year ended december   an increase of  or 
the increase is attributable to the incremental amount of debt issued by the company and outstanding during the comparative periods 
approximately million  in aggregate  of debt was issued between july and december  and was outstanding through the end of june  interest income 
interest income increased to  for the year ended december  from  for the year ended december  the increase of  is due to interest earned on proceeds from the company s initial public offering in june  income tax provision 
due to net losses for the years ended december  and  the company did not incur any federal or state income tax liability for such periods 
the company currently has a net operating loss carryforward in excess of million  however  utilization of such carryforward depends on future earnings and will be subject to annual limitations as a result of changes that have occurred in the company s ownership 
net loss 
net loss decreased to  for the year ended december  from million for the year ended december   a decrease of million 
the loss was reduced primarily as a result of increased sales volume of new and existing products  as discussed above  and the allocation of fixed manufacturing cost and overhead over a greater unit volume 
the year ended december  includes a non recurring charge for stock appreciation rights of approximately million in connection with the company s june  initial public offering  without which the company would have reported net income of  liquidity and capital resources in april   the company completed a public offering resulting in net proceeds of million 
as of december   cash balances were invested in commercial paper  certificates of deposit  money market accounts and us treasury notes 
as of december   the company had approximately million in cash  cash equivalents  and short term investments in marketable securities  and had net working capital of approximately million 
in march  the company entered into a bank credit agreement which matures in april  and provides for up to million of available borrowing at the bank s prime rate 
as of december   no funds have been borrowed under the agreement 
the company used cash in its operations of approximately million for the year ended december  cash used in operations for the period was due  primarily  to the growth in trade accounts receivable and inventories as a result of actual and anticipated growth in sales volume 
during the third quarter of  the company entered into strategic partnerships with unitron and gds 
the agreements with unitron and gds could require the company to pay up to a total of million in cash license fees  in aggregate 
in addition  should the company decide to exercise its right to acquire either unitron or gds  such acquisitions may require additional outlays of cash 
in september   the company initiated a hedging program through the use of forward contracts to minimize foreign currency fluctuation exposure 
as of december   the remaining aggregate us dollar amount of the forward contracts was  and such contracts mature at various dates through september  future liquidity and capital resources could be adversely influenced by certain factors including the company s dependence on a relatively new customer base  regulatory or legislative changes pertaining to health care  product liability exposure regarding the delivery of medication  dependence on future product development  and others 
there can be no assurance that the company will not require additional financing and may  in the future  seek additional funds through bank facilities  debt or equity offerings and to the extent such additional financing is not available  the company could suffer material adverse effects to its financial condition and the results of its operations 
recent accounting pronouncements in june   the financial accounting standards board issued statement of financial accounting standards no 
 reporting comprehensive income 
the company is required to adopt the new standard for periods ending after fiscal this statement establishes standards for reporting and display of comprehensive income and its components in a full set of general purpose financial statements 
the standard requires all items that are required to be recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed in equal prominence with the other financial statements 
the standard is not expected to have a material impact on the company s current presentation of income 
in june   the financial accounting standards board also issued statement of financial accounting standards no 
 disclosures about segments of an enterprise and related information 
the company is required to adopt this new standard for periods ending after fiscal this statement establishes standards for the way companies are to report information about operating segments 
it also establishes standards for related disclosures about products and services  geographic areas  and major customers 
the company is currently evaluating the impact of this standard on its financial statements 
item a 
quantitative and qualitative disclosures about market risk not applicable 

